Evidence-Based Oncology > September

Evidence-Based Oncology – September

August 17, 2012 – This article was sponsored by Eisai Inc. The 2012 Eisai Oncology Digest was commissioned and funded by Eisai Inc.
September 17, 2012
Michael E. Chernew, PhD; Lee N. Newcomer, MD, MHA; and Sandra M. Swain, MD; examine the treatment benefits, cost concerns, and insurance coverage strategies for pertuzumab.
September 18, 2012 – Bruce A. Feinberg, DO; James Lang, PharmD, MBA; James Grzegorczyk, MS, RPh; Donna Stark, RPh, MBA; Thomas Rybarczyk, RN, BSN; Thomas Leyden, MBA; Joseph Cooper; Thomas Ruane, MD; Scott Milligan, PhD;
September 18, 2012 – Marj P. Zimmerman, MS, BSPharm, RPh; and Stanton R. Mehr
September 20, 2012 – Silas Inman
September 20, 2012 – Beth Fand Incollingo
September 20, 2012 – Stanton R. Mehr
September 20, 2012 – Michael Marlan Mohundro, PharmD; and Brice Labruzzo Mohundro, PharmD
Targeted Therapies to Further Improve Outcomes
September 20, 2012 – Linda D. Bosserman, MD, FACP; Diana Verrilli; and Wendy McNatt
September 20, 2012 – John D. Sprandio, MD, FACP
September 20, 2012 – Kim Farina, PhD
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!